A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Inclusion Criteria:
Exclusion Criteria:
Winston-Salem, North Carolina 27103, United States
Bellaire, Texas 77401, United States